AbbVie to acquire ImmunoGen for $10.1B



AbbVie Inc. said on Thursday that it will pay $10.1 billion to acquire ImmunoGen Inc. and its flagship cancer treatment, Elahere, which is used to treat ovarian cancer. The transaction is anticipated …
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento